Testing a new hepatitis B treatment in adults
Part of Digestive system, Infections clinical trials.
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 35 and 65 years old.
- You have been taking a stable nucleoside/nucleotide hepatitis B treatment for at least 6 months.
- Your hepatitis B virus DNA is undetectable (below test limits) for at least two tests in the last month.
- You test negative for hepatitis B e-antigen (HBeAg) and your HBsAg level is between 100 and 1500 IU/mL.
- Your liver enzymes (ALT) are within the normal range.
- You do not have cirrhosis, liver cancer, other liver diseases, or serious health problems like uncontrolled diabetes or high blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, GST-HG131, for people with chronic hepatitis B who are already on stable treatment. It aims to see if the drug is safe and reduces the virus further.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
This study tests a new injection called AHB-137 in people with chronic hepatitis B who have never received antiviral treatment. The goal is to see if it can help reduce the hepatitis B virus in the body and improve liver health.
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
This trial is for people who have already completed a previous study of the drug GST-HG141 (Nairevir) and are now continuing with the same drug plus a nucleoside analog (a standard antiviral). It aims to see how safe and effective this combination is over a longer period.
This study tests a new medicine called ZM-H1505R for people with chronic hepatitis B who are already taking standard antiviral therapy. It aims to see if the new drug can help control the infection better.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.